Humira (adalimumab) / AbbVie - LARVOL DELTA

Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients. (PubMed, BMC Gastroenterol) - "Baseline serum LRG levels > 29 µg/mL demonstrated moderate discriminatory ability for predicting primary non-response to anti-TNF-α therapy in Egyptian IBD patients. LRG may serve as a useful adjunctive biomarker for pre-treatment risk estimation and recognizing patients who may require alternative therapeutic strategies."

Biomarker • Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • LRG1

Legionella Myocarditis with Reversible Left Ventricular Dysfunction in a Patient Receiving Adalimumab: A Case Report. (PubMed, J Investig Med High Impact Case Rep) - "Following a 14-day course of levofloxacin along with supportive care, her cardiac function recovered completely, with a follow-up ejection fraction of 71%. This case highlights the potential for Legionella infection to cause fulminant yet fully reversible myocarditis and underscores the role of TNF-α inhibitor therapy as a predisposing factor for severe Legionella disease. Clinicians should maintain a high index of suspicion for myocarditis in patients with Legionella pneumonia who present with unexplained troponin elevation and new systolic dysfunction, as early recognition and targeted antimicrobial therapy can lead to complete cardiac recovery."

Journal • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Ulcerative Colitis

Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study. (PubMed, Dermatology) - "Both TNF-α and IL-17 inhibitors demonstrate rapid onset of action in HS. However, IL-17 inhibitors may offer superior mid-term durability of response, supporting their role as a preferred option for sustained disease control."

HEOR • Journal • Real-world evidence • Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Oncology • IL17A

Biologic Therapy in Refractory Non-Infectious Uveitis: An Analysis of 60 Cases at a Tertiary Eye Care Centre from South India. (PubMed, Ocul Immunol Inflamm) - "Adalimumab was the most frequently used biologic agent (88.3%) followed by Infliximab (5%), golimumab (3.3%) and tocilizumab (3.3%). Biologic therapy is an effective and safe therapy for refractory non-infectious uveitis across all age-groups and etiologies. Early escalation to biologics may help arrest long-term cumulative inflammatory damage and preserve visual function by sustained inflammatory control."

Journal • Idiopathic Arthritis • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics • Rheumatology • Uveitis

Development and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes. (PubMed, J Pharm Biomed Anal) - "Four IC models with known epitopes (tumor necrosis factor alpha-adalimumab, tumor necrosis factor alpha-infliximab, human epidermal growth factor receptor 2-pertuzumab, and human epidermal growth factor receptor 2-trastuzumab) were analyzed using three cross-linkers of different lengths: bis(sulfosuccinimidyl) suberate (BS3), bis(sulfosuccinimidyl) glutarate (BS2G), and 1,1'-carbonyldiimidazole (CDI). These findings demonstrate that FR-targeted XL-MS provides a strategy for identifying epitopes within patient-derived IC-antigens through the use of conserved antibody FRs. This approach may contribute to understanding antigen recognition mechanisms in autoimmune diseases and support the discovery of disease-relevant therapeutic targets."

Journal • Hepatology • Immunology • Oncology • Primary Biliary Cholangitis • HER-2 • TNFA

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events (clinicaltrials.gov) - P4 | N=32 | Completed | Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Sun Yat-sen University | Not yet recruiting ➔ Recruiting

Enrollment open • pMMR • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

Drug survival of adalimumab across different manifestations of Behçet's syndrome: a retrospective analysis in 335 patients. (PubMed, Rheumatology (Oxford)) - "ADA showed a good retention rate at month 6, followed by a gradual decline in drug retention over time. Secondary inefficacy was the most common reason for treatment discontinuation, followed by adverse events and non-compliance, whereas primary inefficacy was uncommon. Dose intensification to achieve active disease control and dose de-escalation in patients with sustained remission may be feasible management strategies."

Journal • Retrospective data • Oncology • Rare Diseases

Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea. (PubMed, Ocul Immunol Inflamm) - "One patient received prior infliximab; within the previous 3 months, 75.4% and 93.3% of patients received glucocorticoids and immunosuppressants, respectively. Regarding effectiveness, from baseline to 22 weeks, anterior chamber inflammation and vitreous haze tended to improve significantly; there was no BCVA worsening. In the real-world setting, adalimumab treatment showed an acceptable safety profile, with serious AEs reported in three patients but no serious ADRs related to adalimumab, and demonstrated potential effectiveness in Korean patients with NIIPPU."

Journal • P4 data • Real-world evidence • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Ulcerative Rectosigmoid Langerhans Cell Histiocytosis Mimicking Late-Onset Inflammatory Bowel Disease (ACG 2026) - "She had a history of indeterminate colitis diagnosed in 2023 with patchy colonic and small bowel involvement requiring multiple targeted immune modulating (TIM) therapies including vedolizumab, Risankizumab, infliximab, adalimumab, and azathioprine...On admission, she was found to have a Clostridium difficile infection and was started on fidaxomicin with clinical response...The patient was re-started on targeted LCH therapy with dabrafenib by hematology and nutritional support via total parenteral nutrition...B: On higher magnification, the lamina propria contains patchy histiocytic infiltrates, which are accompanied by scattered eosinophils and are in close association with colonic crypts with crypt injury, cryptitis and crypt abscesses (hematoxylin-eosin stains at 200x). C: CD1a immunohistochemistry is strongly and diffusely positive in the histiocytic infiltrates, supporting the diagnosis of Langerhans cell histiocytosis (CD1a stain, 200x)."

CNS Disorders • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Langerhans Cell Histiocytosis • CD1a

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants. (PubMed, World J Clin Pediatr) - "Variants in the TNFRSF1A gene may cause a wide range of clinical symptoms, including eye and intestinal lesions that are not typical of sJIA. All patients with fever and unusual sJIA symptoms should have molecular genetic testing for TNFRSF1A variants to confirm or exclude AID early. Early diagnosis enables timely therapy and prevents complications. Tocilizumab (39.3%), canakinumab (33.3%), and TNF inhibitors (21.2%) achieved remission in children with TNFRSF1A variants. Some patients required multiple bDMARD switches to achieve remission, highlighting the complexity of treatment decisions in this group."

Journal • Amyloidosis • CNS Disorders • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Oncology • Otorhinolaryngology • Pain • Pediatrics • Rheumatology • Ventriculomegaly • TNFRSF1A

When anti-tumor necrosis factor-α backfires: paradoxical psoriasis and psoriatic arthritis in a patient with hidradenitis suppurativa. (PubMed, Dermatol Reports) - "Recently, interleukin (IL)-17 inhibitors (secukinumab, bimekizumab) were also approved in Europe for moderate-to-severe HS. We report a case of paradoxical inverse psoriasis and suspected early psoriatic arthritis induced by adalimumab in an HS patient, successfully managed by switching to secukinumab. [...]."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • TNFA

A case report of ADMIO type 1 caused by a de novo STAT3 gain-of-function mutation. (PubMed, Front Immunol) - "Initial treatment with tocilizumab provided short-lived benefit. Following recurrent lymphadenitis and polyarthritis, adalimumab, tofacitinib, ruxolitinib emerged as a key anti-inflammatory intervention to treat the disease. This case enriches the rare disease database and helps raise clinicians' awareness of and attention to ADMIO type 1 disease."

Journal • Immunology • Rare Diseases • Rheumatology • Vasculitis • STAT3

Medically Refractory Acute Severe Ulcerative Colitis Complicated by Cytomegalovirus Managed With Diverting Loop Ileostomy During Pregnancy: A Case Report (ACG 2026) - "Case Description/ A 23-year-old woman with a 10-year history of ulcerative pancolitis being treated with upadacitinib 45mg and prednisone 40mg was transferred from another hospital at 25 weeks gestation with 2 weeks of bloody diarrhea. She had loss of response or non-response to adalimumab, vedolizumab, ustekinumab, and prior response to infliximab induction but lost response after switching to subcutaneous maintenance...Intravenous solumedrol was started on day 1 and upadacitinib was continued...She continued infliximab and valganciclovir and tapered off prednisone outpatient...Secondly, the management of CMV colitis during pregnancy may differ from non-pregnant individuals, as ganciclovir is typically avoided due to potential risks to the fetus...Figure: Figure 1: Representative image from flexible sigmoidoscopy showing severe colitis with erythema and ulcerations. Figure: Figure 2: Picture of the patientâs ostomy wound two weeks post-op."

Case report • Clinical • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update. (PubMed, J Dermatolog Treat) - "For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options. These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients."

Clinical guideline • Journal • Review • Dermatology • Immunology • Oncology • Pediatrics • Psoriasis • IL12A • IL23A

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Drug-Associated Colitis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) (ACG 2026) - "A total of 46,511 reports of colitis were identified, of which 42,550 (91.5%) were serious and 3,797 (8.2%) involved death. Disproportionality analysis demonstrated signals for the drugs with the strongest associations observed for ipilimumab (n=2091; ROR 46.95; 95% CI 44.87-49.11), nivolumab (n=2260; ROR 19.23; 95% CI 18.42-20.07), pembrolizumab (n=1933; ROR 15.86; 95% CI 15.14-16.60), vedolizumab (n=1342; ROR 12.37; 95% CI 11.71-13.07), carboplatin (n=1324; ROR 8.62; 95% CI 8.16-9.11), infliximab (n=1680; ROR 5.81; 95% CI 5.54-6.11), prednisone (n=1348; ROR 5.25; 95% CI 4.97-5.55), methotrexate (n=1327; ROR 4.67; 95% CI 4.42-4.94), adalimumab (n=3937; ROR 4.39; 95% CI 4.25-4.53) and cyclophosphamide (n=1029; ROR 4.33; 95% CI 4.07-4.61). Ipilimumab demonstrated the strongest signal for colitis, consistent with the established risk of immune-mediated GI toxicity (1)."

Adverse events • Gastroenterology • Gastrointestinal Disorder • Immunology • Solid Tumor

Cross-Sectional Analysis of Biologic Use in the Treatment of Veterans With Hidradenitis Suppurativa. (PubMed, Fed Pract) - "Biologic medications, such as adalimumab, secukinumab, and bimekizumab, are currently the only medications approved by the US Food and Drug Administration for the treatment of hidradenitis suppurativa (HS)...Biologic prescriptions, including adalimumab and infliximab, were analyzed across varying patient demographics and characteristics...Biologic use in patients with HS was relatively low but higher or within the same range as previous studies. Understanding biologic prescription patterns offers potential to identify and improve access to underserved HS populations."

Journal • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Obesity

Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study. (PubMed, Psoriasis (Auckl)) - "Limitations include the retrospective single-center design, modest sample size, treatment imbalance, surrogate outcomes, and potential residual confounding. Compared with adalimumab, secukinumab was associated with more favorable longitudinal BMD trajectories and a bone turnover profile consistent with increased formation and reduced resorption in patients with psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries. (PubMed, Paediatr Drugs) - "Efforts to expedite approval of new agents in pIBD are warranted to ensure timely access to effective medications. Consideration for novel trial designs alongside continued engagement with regulatory bodies, sponsors, and the academic pIBD community is essential to advance drug approvals for pIBD."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics

Eosinophilic Ulcerative Colitis Following Appendectomy for Appendiceal Adenocarcinoma: A Challenging Therapeutic Course (ACG 2026) - "Initial treatment with mesalamine and a budesonide yielded symptomatic improvement, but patient experienced a relapsing-remitting course refractory to multiple biologic agents, including two doses of vedolizumab, one dose of ustekinumab, three months of biweekly adalimumab, and currently post three doses of guselkumab...He was confirmed to have positive small bowel bacterial overgrowth based on breath test and completed 3 weeks of rifaximin and neomycin with some improvement...No active colitis. Numerous pseudopolyps and inflammatory polyps in the range of 2cm throughout colon."

Appendix Cancer • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "This review has supported evidence generation, but head-to-head comparative trials for key interventional subclasses or specific agents may be needed, as guided by key stakeholders; for example, on the use of biosimilar versions of medications out of patent. The role of concomitant purine analogues is a key confounding factor and future studies may not only want to investigate specifically the role of combinations, but also consider stratifying populations or purposefully excluding participants based on this key class of therapy to avoid such heterogeneity. Given the majority of evidence focusses on the outcomes of clinical remission and relapse, future studies may want to further consider other outcomes of clear interest to clinicians and patients, particularly endoscopic remission. Finally, long-term safety data are limited throughout the networks. Whilst future studies with longer follow-ups could provide increased data, it may be that study designs outside of..."

Clinical • Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL7R

Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95% CI 0.42â0.70;..."

Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A